Canine osteosarcoma checkpoint expression correlates with metastasis and T-cell infiltrate

2021 ◽  
Vol 232 ◽  
pp. 110169
Author(s):  
Matthew J. Cascio ◽  
Elizabeth M. Whitley ◽  
Bikash Sahay ◽  
Galaxia Cortes-Hinojosa ◽  
Lung-Ji Chang ◽  
...  
1995 ◽  
Vol 33 (2) ◽  
pp. 341-345 ◽  
Author(s):  
Michael S Metzman ◽  
Seth R Stevens ◽  
Christopher E.M Griffiths ◽  
Charles W Ross ◽  
Jay M Barnett ◽  
...  

2007 ◽  
Vol 138 (3) ◽  
pp. 316-323 ◽  
Author(s):  
M. Ponzoni ◽  
F. Berger ◽  
C. Chassagne-Clement ◽  
M. Tinguely ◽  
A. Jouvet ◽  
...  

Cancers ◽  
2021 ◽  
Vol 13 (17) ◽  
pp. 4394
Author(s):  
Julie Lecuelle ◽  
Romain Boidot ◽  
Hugo Mananet ◽  
Valentin Derangère ◽  
Juliette Albuisson ◽  
...  

Purpose: Immune infiltration is a prognostic factor in high-grade serous ovarian carcinoma (HGSC) but immunotherapy efficacy is disappointing. Genomic instability is now used to guide the therapeutic value of PARP inhibitors. We aimed to investigate exome-derived parameters to assess the tumor microenvironment according to genomic instability profile. Methods: We used the HGSC TCGA (the cancer genome atlas) dataset with genomic characteristics, including homologous recombination deficiency (HRD), copy number variant (CNV) signatures, TCR (T cell receptor) clonality and abundance of tissue-infiltrating immune and stromal cell populations. We then investigated the relationship with survival data. Results: In 578 HGSC patients, HRD status, CNV signature 7 and TCR clonality were associated with longer survival. The combination of high CNV signature 7 expression and HRD status or high CNV signature 3 expression and high TCR clonality was associated with a trend towards longer survival compared to each variable alone. Combining T cell infiltrate and TCR clonality improved the prognostic value compared to T cells infiltration alone. Prognostic value of TCR clonality was confirmed in an independent cohort. Conclusions: TCR clonality is an emerging prognostic biomarker that improves T cell infiltrate information. Analysis of TCR clonality combined with genomic instability could be an interesting prognostic biomarker.


2008 ◽  
Vol 50 (3) ◽  
pp. 139-139
Author(s):  
Ana Giménez-Arnau ◽  
A Toll ◽  
F Gallardo ◽  
J Roman ◽  
RM Pujol-Vallverdú
Keyword(s):  
T Cell ◽  

2016 ◽  
Vol 213 (13) ◽  
pp. 2835-2840 ◽  
Author(s):  
Antoni Ribas ◽  
Siwen Hu-Lieskovan

Expression of the programmed death-1 (PD-1) ligand 1 (PD-L1) is used to select patients and analyze responses to anti–PD-1/L1 antibodies. The expression of PD-L1 is regulated in different ways, which leads to a different significance of its presence or absence. PD-L1 positivity may be a result of genetic events leading to constitutive PD-L1 expression on cancer cells or inducible PD-L1 expression on cancer cells and noncancer cells in response to a T cell infiltrate. A tumor may be PD-L1 negative because it has no T cell infiltrate, which may be reversed with an immune response. Finally, a tumor that is unable to express PD-L1 because of a genetic event will always be negative for PD-L1 on cancer cells.


2009 ◽  
Vol 16 (9) ◽  
pp. 2524-2530 ◽  
Author(s):  
Steven C. Katz ◽  
Venu Pillarisetty ◽  
Zubin M. Bamboat ◽  
Jinru Shia ◽  
Cyrus Hedvat ◽  
...  

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 1873-1873
Author(s):  
Ryan J. Stubbins ◽  
James Zhu ◽  
Raymond Lai ◽  
Carolyn J. Owen ◽  
Jutta Preiksaitis ◽  
...  

Abstract Introduction The host immune status is central to both the pathogenesis and treatment of Post-Transplant Lymphoproliferative Disorders. (PTLD) The most commonly used prognostic model for PTLD, the International Prognostic Index (IPI), currently does not account for the effect of immune status on patient outcomes. We hypothesize that CD3 positive T-cell infiltrate density in the tumor microenvironment, thought to be a surrogate of the potency of the host versus tumor immune response, may be prognostic of overall survival in PTLD. Methods A database consisting of 131 biopsy confirmed PTLD cases occurring in pediatric and adult solid organ transplant recipients after the year 2000 in Alberta, Canada was analyzed for clinical prognostic variables and overall survival. CD3 infiltrate was determined by a blinded pathologist (JZ) using a standardized integer scoring system (0 - 3) to quantify CD3-positive cells in archived, formalin-fixed paraffin embedded tissue stained by immunohistochemistry. Tissue was available and assessed on a total of 72 patients. Survival analysis was done by Cox regression, with between group differences tested by a Pearson's chi-square test, with p < 0.05 being taken as significant. Results Median age at diagnosis was 40.2 years. Histology subtypes included early (n = 7), polymorphic (n = 17), monomorphic, (n = 100) Hodgkin, (n = 8) and unavailable. (n = 2) Immune suppression regimens at diagnosis included tacrolimus + mycophenolate (n = 29), tacrolimus + azathioprine (n = 11), cyclosporine + mycophenolate (n = 14), cyclosporine + azathioprine (n = 4), single agent tacrolimus (n = 11), single agent cyclosporine (n = 2), and other immunosuppressive regimens. (n = 4) A denser CD3 T-cell infiltrate, defined as a CD3 score of 2-3, had a statistically significant protective effect by univariate Cox regression with respect to overall survival. (HR 0.352, p = 0.008) A CD3 score of 2-3 was negatively associated with a monomorphic histology (p < 0.001), but was not statistically associated with lymphocyte count, early PTLD, EBV status or bone marrow involvement. In the diffuse large B-cell type PTLD subgroup (n = 61) the association of a dense CD3 T-cell infiltrate with an improved OS was preserved. (HR 0.276, p = 0.041) Clinical factors identified as significant by univariate Cox regression with respect to overall survival included age < 18 (HR = 0.380, p = 0.010), monomorphic histology (HR = 2.287, p = 0.02), IPI 3-5 (HR = 3.697, p < 0.001), BM involvement (HR 2.437, p = 0.008), and lymphocyte count < 1.0. (HR 2.449, p = 0.001) Clinical factors deemed to not be significant with respect to overall survival by univariate Cox regression included CD20 (p = 0.730), thoracic transplant organ (p = 0.314), PTLD onset within 1 year of transplant (p = 0.763), allograft involvement (p = 0.253), albumin of < 30 (p = 0.062) and tumor EBV status. (p = 0.278) Multivariate Cox regression with respect to overall survival, including monomorphic histology, IPI 3-5, lymphocyte count < 1.0 and CD3 score of 2-3 again showed a statistically significant protective effect of a higher CD3 score. (HR 0.307, p = 0.022) No other clinical variables reached significance in the multivariate analysis. Conclusions A dense CD3 T-cell infiltrate in the tumor microenvironment at diagnosis is protective with regards to overall survival in PTLD by both univariate and multivariate Cox regression, versus traditional clinical prognostic markers. This is reflective of the prognostic importance of the host immune response, which can be altered by changes in exogenous immunosuppression. In the future, validated histologic measures of immune status such as the CD3 score may be integrated into existing models, such as the IPI, to provide additional prognostic power in PTLD. Table 1 Baseline Patient Characteristics - A database with 131 pediatric and adult solid organ transplant recipients with PTLD were analyzed for clinical prognostic factors and available formalin fixed paraffin embedded tissue stained for CD3 by immunohistochemistry. Table 1. Baseline Patient Characteristics - A database with 131 pediatric and adult solid organ transplant recipients with PTLD were analyzed for clinical prognostic factors and available formalin fixed paraffin embedded tissue stained for CD3 by immunohistochemistry. Table 2 CD3 Score by Univariate Analysis - A univariate Cox regression was carried out for a CD3 score of 2-3 versus 0-1 for all analyzed samples. (n = 72) * denotes the reference variable. Table 2. CD3 Score by Univariate Analysis - A univariate Cox regression was carried out for a CD3 score of 2-3 versus 0-1 for all analyzed samples. (n = 72) * denotes the reference variable. Table 3 CD3 score by Multivariate Analysis versus Clinical Factors - A multivariate Cox regression was performed for a CD3 score of 2-3, versus selected clinical factors identified by univariate Cox regression. Table 3. CD3 score by Multivariate Analysis versus Clinical Factors - A multivariate Cox regression was performed for a CD3 score of 2-3, versus selected clinical factors identified by univariate Cox regression. Disclosures Owen: Janssen: Honoraria; Gilead: Honoraria, Research Funding; Pharmacyclics: Research Funding; Celgene: Honoraria, Research Funding; Abbvie: Honoraria; Lundbeck: Honoraria, Research Funding; Novartis: Honoraria; Roche: Honoraria, Research Funding.


2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 5547-5547
Author(s):  
J. Kim ◽  
S. Kim ◽  
J. Choi ◽  
B. Shin ◽  
S. Yoon ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document